Trial Profile
A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy(JBCRG-04)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- Acronyms CREATE-X
- 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 09 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 01 Jun 2017 Primary endpoint (Disease-free survival) has been met as per the results published in the New England Journal of Medicine